Li et al. (2019) discovered 13 key T2DM targets and found that A. membranaceus can treat T2DM by upregulating the activity of casein kinase, by ensuring the normal regulation of lipid metabolism, and by enhancing insulin resistance, thereby upregulating insulin signaling. Several key targets were randomly selected for quantitative real-time PCR validation, and the results indicated that the analysis of network pharmacology was robust and targets identified via this process were worthy of validation (Li et al., 2019). The gene discussed is PDIK1L; the disease is Insulin resistance.